Mar 11, 2025
Moleculin Biotech, Inc. Participates in the Virtual Investor "Top 5 for '25" On-Demand Conference
Mar 10, 2025
Moleculin to Present at the 37th Annual ROTH Conference
Mar 06, 2025
Moleculin Announces Additional Annamycin Patent Allowances to Enhance Global Exclusivity
Mar 03, 2025
Moleculin Abstract Accepted for Poster Presentation at the Acute Leukemias XIX (ISALXIX) International Symposium
Feb 25, 2025
Moleculin Announces Pricing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At The Market Under Nasdaq Rules
Feb 13, 2025
Moleculin Announces Exercise of Warrants for $5.8 Million Gross Proceeds
Feb 11, 2025
Moleculin Receives First Country Approval in Europe to Begin Recruiting for the MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial
Jan 27, 2025
Moleculin Participates in Virtual Investor "What This Means" Segment
Nov 12, 2024
Moleculin Receives Institutional Review Board Approval for MIRACLE Phase 3 Pivotal Trial of Annamycin in Combination with Cytarabine for the Treatment of R/R Acute Myeloid Leukemia (AML)
Nov 11, 2024
Moleculin Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Nov 04, 2024
Moleculin Appoints Leading Expert in Pancreatic Cancer to its Scientific Advisory Board to Support Development of Annamycin
Oct 07, 2024
Moleculin to Host Virtual Acute Myeloid Leukemia KOL Event on October 14, 2024
Oct 04, 2024
Moleculin to Present at Two Upcoming Investor Conferences
Sep 23, 2024
Moleculin Announces Positive In Vivo Efficacy Data of Annamycin in Orthotopic and Experimental Lung Metastatic Models of Sarcoma
Sep 16, 2024
Moleculin Participates in Virtual Investor "What this Means" Segment
Sep 09, 2024
Moleculin Announces First Patients Treated in Phase 2 Clinical Trial of STAT3 Inhibitor in Combination with Radiation for the Treatment of Glioblastoma
Aug 19, 2024
Moleculin Announces Closing of up to $16.5 Million Public Offering
Aug 16, 2024
Moleculin Announces Pricing of up to $16.5 Million Public Offering
Aug 14, 2024
Moleculin Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Aug 05, 2024
Moleculin to Host Webcast Presentation to Discuss Recently Announced Plans for MIRACLE Phase 3 Pivotal Trial Tuesday, August 6, 2024 at 8:30 AM ET